236 related articles for article (PubMed ID: 31034937)
1. Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.
Meyer KA; Deraedt MF; Harrington AT; Danziger LH; Wenzler E
Int J Antimicrob Agents; 2019 Aug; 54(2):197-201. PubMed ID: 31034937
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
3. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.
Luther MK; Arvanitis M; Mylonakis E; LaPlante KL
Antimicrob Agents Chemother; 2014 Aug; 58(8):4612-20. PubMed ID: 24867993
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model.
Skinner K; Sandoe JAT; Rajendran R; Ramage G; Lang S
Int J Antimicrob Agents; 2017 Apr; 49(4):507-511. PubMed ID: 28235571
[TBL] [Abstract][Full Text] [Related]
5. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
8. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
10. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of oritavancin and nisin alone and their combination against vancomycin resistant enterococci strains in hospitalized patients in Turkiye.
Sefali S; Y N
Indian J Med Microbiol; 2024; 47():100489. PubMed ID: 37890415
[TBL] [Abstract][Full Text] [Related]
12. The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections.
Kramer TS; Remschmidt C; Werner S; Behnke M; Schwab F; Werner G; Gastmeier P; Leistner R
Antimicrob Resist Infect Control; 2018; 7():133. PubMed ID: 30459945
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci.
Yan Q; Karau MJ; Patel R
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):348-350. PubMed ID: 29678300
[TBL] [Abstract][Full Text] [Related]
14. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.
Mendes RE; Woosley LN; Farrell DJ; Sader HS; Jones RN
Antimicrob Agents Chemother; 2012 Mar; 56(3):1639-42. PubMed ID: 22183169
[TBL] [Abstract][Full Text] [Related]
15.
Brown Gandt A; Griffith EC; Lister IM; Billings LL; Han A; Tangallapally R; Zhao Y; Singh AP; Lee RE; LaFleur MD
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784838
[TBL] [Abstract][Full Text] [Related]
16. In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant
Tong J; Jiang Y; Xu H; Jin X; Zhang L; Ying S; Yu W; Qiu Y
Drug Des Devel Ther; 2021; 15():3049-3055. PubMed ID: 34285472
[TBL] [Abstract][Full Text] [Related]
17. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an
Belley A; Lalonde-Séguin D; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
[TBL] [Abstract][Full Text] [Related]
18. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children.
Tamma PD; Hsu AJ
Curr Opin Infect Dis; 2014 Dec; 27(6):517-27. PubMed ID: 25313503
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.
Dahesh S; Wong B; Nizet V; Sakoulas G; Tran TT; Aitken SL
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235559
[TBL] [Abstract][Full Text] [Related]
20. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.
Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
